Use of the Leva Incontinence System in Treating Bladder Incontinence.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- New England Spine Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Subjects must be female.
- Subjects must be capable of giving informed consent.
- Subjects should be at least 18 years of age and less than 89 years of age
- Subjects must have a diagnosis of or symptoms of predominant mild to moderate urinary incontinence based on the results of the completed urinary incontinence surveys.
Exclusion Criteria:
- Absence of a vagina.
- Positive drug or alcohol test at the screening visit.
- Post-menopausal defined as absence of a period for over 12 months.
- Pregnancy or being less than 12 months post-partum.
- Greater than three vaginal deliveries or prior operative delivery (e.g. use of vacuum, forceps or abdominal pressure).
- Symptoms of stage II or greater pelvic organ prolapse.
- BMI >31 kg/m2.
- Diagnosis of any neurological disorder.
- Prior lower back or pelvic surgery, including prior surgery for stress urinary incontinence (SUI).
- Prior pelvic radiation.
- Current or recurrent vaginal infections (>three per year).
- Painful bladder syndrome, active or chronic pelvic pain.
- Concurrent Pelvic Floor Muscle Exercises (PFME) under a supervised therapeutic plan of care.
- Previous supervised pelvic floor muscles rehabilitation in the past 12 months for the treatment for urinary incontinence or any other pelvic floor disorder.
- Currently taking medication to treat incontinence.
- Impaired cognitive function.
- Unable to tolerate use of the leva device.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Leva Arm
Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
|
The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptoms of Urinary Incontinence at Baseline and at 6 Weeks
Time Frame: 6 weeks
|
A validated, standardized questionnaire (the short form of the urogenital distress inventory, UDI-6) will be used to evaluate change in symptoms of urinary incontinence.
Minimum score = 0, Maximum score = 100, lower scores indicate fewer symptoms.
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Condition-specific Quality of Life Assessment (IIQ-7) at Baseline and 6 Weeks.
Time Frame: 6 weeks
|
Condition specific quality of life as it is affected by urinary incontinence will be assessed using the Incontinence Impact Questionnaire (IIQ-7).
Minimum value 0, Maximum value 100, lower scores indicate improvement.
|
6 weeks
|
|
Number of Participants for Different Categories of Patient Global Impression of Improvement (PGI-I)
Time Frame: At 6 weeks
|
Subject perception of improvement will be evaluated using the standardized survey Patient Global Impression of Improvement (PGI-I).
Categories of improvement include: Very Much Better, Much Better, A Little Better, No Change, Worse(any degree).
|
At 6 weeks
|
|
Pelvic Floor Muscle Performance (Mean Maximum Duration of Voluntary Pelvic Floor Muscle Contraction)
Time Frame: 6 weeks
|
Change in pelvic floor muscle performance will be evaluated using muscle performance testing performed using the leva device.
Subjects were asked to lift and squeeze pelvic floor muscles for as long as possible.
The length of time a subject can "hold" the lift was recorded
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert Rosenberg, MD, New England Spine Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- REN-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.